Kalpataru Acquisition Worth ₹52.55 Cr

Kalpataru Earnings Call Transcript: Key Takeaways

Kalpataru celebrated its listing year with high completions but faces shareholder scrutiny over stock performance and project transparency.

Kalpataru Other Announcement

Kalpataru filed CARE Ratings' IPO monitoring report for the quarter ended September 30, 2026. It reports no deviation from offer objects, though fund co-mingling was noted.

Kalpataru Results Update

Kalpataru's Q2 FY27 revenue was Rs.437 Crore with a Rs.71 Crore PAT loss. Pre-sales fell 5% year-on-year, while collections stayed flat.

Kalpataru Investor Presentation: Key Takeaways

Q2 FY27 revenue fell 45% YoY to ₹437 Cr with a ₹71 Cr loss. Pre-sales were ₹1,258 Cr (-5% YoY). Growth rests on MMR and Pune launches and redevelopment.

Kalpataru Q2 FY27 Results: Net Loss of ₹70.7 Cr

Kalpataru Ltd reported revenue from operations of ₹437.2 Cr (-44.9% YoY) and a net loss of ₹70.7 Cr for Q2 FY27.

Key figure

Net loss ₹70.7 Cr

Kalpataru Board Meeting Date

Kalpataru Ltd scheduled its Board meeting for 29 Oct 2026 to consider Q2 and H1 2026 financial results. No decision has been taken yet.

Zydus Lifesciences Acquisition Worth ₹84 Cr

Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.

Value

₹84.00 Cr

Zydus Lifesciences Acquisition Worth ₹167 Cr

Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.

Value

₹167.0 Cr

Zydus Lifesciences Acquisition

Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.

Arvaya Healthcare Acquisition

Arvaya Healthcare completed the acquisition of 100% equity in Sushodha Institute of Gastroenterology Private Limited on 1 November 2026. The target is now a wholly-owned subsidiary, with no consideration amount disclosed.

Affle 3I Acquisition Worth ₹3,990 Cr

Affle 3i's step-down subsidiary will acquire Perion Network in an all-cash deal valued at about ₹3,990 Crore. Closing is expected in early 2027.

Value

₹3,990 Cr

Execution

Expected to close in early 2027

Sai Parenterals Acquisition

Sai Parenterals will acquire the remaining 25% stake in its 75% subsidiary SP Analytics for cash, making it wholly owned. Related-party approval was taken at the 1 November 2026 board meeting, with completion by 31 December 2026.

Execution

31-12-2026